Solid gets another shot in DMD gene therapy race as FDA lifts hold. But is it too late to catch Pfizer, Sarepta?
Things can get moving again in Worcester, Massachusetts and Gainesville, Florida, where Solid Biosciences operate their clinical sites.
Nearly a year after the FDA suspended Solid’s Duchenne muscular dystrophy gene therapy trial over safety concerns for a second time, the agency has given the Cambridge biotech the go-ahead to start dosing again. The trial will likely resume in the first quarter of next year, CSO Carl Morris said in a statement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,600+ biopharma pros reading Endpoints daily — and it's free.